Patients taking the Johnson & Johnson psoriasis drug experienced a significant reduction in the skin condition after 12 weeks, researchers report. The study involving about 1,230 patients found that more than two-thirds of patients who received the drug reported at least a 75% reduction in the severity of the skin disease within three months. J&J, which plans to file for regulatory approval of the drug this year, is also testing the compound as a possible treatment for Crohn's disease.

Related Summaries